# Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

> **NCT01458392** · PHASE2 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 46 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** Dalantercept

## Key facts

- **NCT ID:** NCT01458392
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458392, "Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01458392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*